Published • loading... • Updated
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
Summary by The Bakersfield Californian
3 Articles
3 Articles
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences
VANCOUVER, British Columbia & GRAPEVINE, Texas -- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP), taking place April 16-20, 2026 and the Neuroscience Education Institute (NEI) Spring Congres…
·Toronto, Canada
Read Full Article
The Bakersfield CalifornianReposted by 
Hastings Tribune
Hastings TribuneAlpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Mar 10, 2026-
·Bakersfield, United States
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
